This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lu
A phase 3 trial of Pembrolizumab in non-small-cell lung cancer and small-cell lung cancer, run by Pfizer, now recruiting.
Overview
This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1. is a phase 3 interventional study registered as NCT06758401 by Pfizer, with 714 participants planned, started 2025-07-23 and due to reach its primary completion in 2028-09-05. Interventions recorded: Sigvotatug Vedotin, Pembrolizumab. Conditions listed: Non-Small Cell Lung Cancer, Carcinoma, Non-Small-Cell Lung, Carcinoma, Non-Small-Cell Lung (NSCLC). No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialSymbiotic-Lung-10: A Study to Learn About PF-08634404 Alone or in Combination in Early-stage or Locally Advanced NSCLC
Shares Pfizer (incl. Seagen), Small-cell lung cancer, Non-small-cell lung cancer.
- TrialSymbiotic-Lung-14: A Study to Learn About the Study Medicine Called PF08634404 in Combination With Chemotherapy in Adult Participants With Transformed
- TrialSymbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
- TrialSymbiotic-Lung-04: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Extensive-Stage Small Cell Lung Cancer
- TrialSymbiotic-Lung-20: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers
Shares Pfizer (incl. Seagen), Small-cell lung cancer, Non-small-cell lung cancer.
- TrialA Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
- TrialA Study of Encorafenib Plus Cetuximab Taken Together With Pembrolizumab Compared to Pembrolizumab Alone in People With Previously Untreated Metastatic
Shares Pfizer (incl. Seagen), Pembrolizumab.
- TrialA Study to Find Out if Enfortumab Vedotin Given With Pembrolizumab Helps People With Muscle-invasive Bladder Cancer Keep Their Bladder
Shares Pfizer (incl. Seagen), Pembrolizumab.